Gemtuzumab ozogamicin
- Generic Name
- Gemtuzumab ozogamicin
- Brand Names
- Mylotarg
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 220578-59-6
- Unique Ingredient Identifier
- 8GZG754X6M
- Background
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody . The antibody ...
- Indication
Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial tr...
- Associated Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005962
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธHahnemann University Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธCCOP - Columbus, Columbus, Ohio, United States
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00070174
- Locations
- ๐บ๐ธ
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
๐บ๐ธSt. Barnabas Medical Center, Livingston, New Jersey, United States
๐บ๐ธAll Children's Hospital, St. Petersburg, Florida, United States
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-27
- Target Recruit Count
- 472
- Registration Number
- NCT00052299
- Locations
- ๐ฎ๐น
Ospedale San Bortolo, Vicenza, Italy
๐ณ๐ฑOnze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
๐ฆ๐นA. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung, Linz, Austria
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Genta Incorporated
- Registration Number
- NCT00017589
- Locations
- ๐บ๐ธ
Genta Incorporated, Berkeley Heights, New Jersey, United States
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 33
- Registration Number
- NCT00049179
- Locations
- ๐บ๐ธ
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
๐บ๐ธKennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States
๐บ๐ธDavid C. Pratt Cancer Center at St. John's Mercy, St. Louis, Missouri, United States
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 47
- Registration Number
- NCT00028899
- Locations
- ๐บ๐ธ
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
๐บ๐ธCancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States
๐บ๐ธAlvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00037596
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT00037583
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.